Si cdr1as

The RNA oligoribonucleotides used in this study, including miR-1270 mimic, miR-1270 inhibitor, the small interfering RNAs (siRNAs) targeting CDR1as (si-CDR1as) or SCAI (si-SCAI), and the corresponding miRNA control (miR-NC) and siRNA control (si-NC), were purchased from GenePharma (Shanghai, China). The RNA oligoribonucleotides used in this study, including miR-1270 mimic, miR-1270 inhibitor, the siRNAs targeting CDR1as (si-CDR1as) or SCAI (si-SCAI), and the corresponding miRNA control (miR-NC) and siRNA control (si-NC), were purchased from GenePharma (Shanghai, China).
The lentivirus targeting human CDR1as was purchased from GeneChem (Shanghai, China). The targeting sequence was designed as follows: 1 sense 5′-TGCACCTGTGTCAAGGTCTTTTCAAGAGAAAGACCTTGACACAGGTGCTTTTTTC-3′ and 2 sense 5′-TGGTCTTCCAGCGACTTCAATTCAAGAGATTGAAGTCGCTGGAAGACCA-3′. miR-7 mimics and inhibitors were synthesized by RiboBio. The miRNA oligonucleotides were transfected using Lipofectamine RNAiMAX (50 nmol/L; Invitrogen, CA, USA).

Cells were seeded into six‐well plates at a density of 6 × 10⁴ cells/2 ml/well and maintained in an incubator at 37 °C, 5% CO₂. When the cells reached about 80% confluency, cell transfection was performed. pcDNA3‐CDR1as and its negative control (which had an inserted CDR1as sequence only but no invert repeat flanking introns into the pcDNA3.1‐empty plasmid, resulting in no circular CDR1as), si‐CDR1as, were conducted by GenePharma (Shanghai, China). miR‐135b mimics or negative control was purchased from RiboBio (Guangzhou, People's Republic of China). BMECs were transfected with plasmids or oligonucleotides using Lipofectamine™ 2000 (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. After 24 h of transfection, the efficiency of transfection was determined by qRT‐PCR.